Technological survey on LIMS and ELN in Life Sciences - Biogenouest

More documents

Recommendations

Info

Introduction 1 -‐ The European project ShareBiotech The European project ShareBiotech gathers 4 countries: Ireland, France, Spain andPortugal. The objective of this project is to strengthen the biotechnology sector withinthe Atlantic Area and improve the service offer of the technological core facilitiesinvolved in the project. ShareBiotech notably aims at making technological corefacilities more accessible to companies – and specifically small & mediumenterprises (SMEs) – working in the field of human health, nutrition, agriculture/foodprocessing,cosmetics, marine biology and environment. Providing companies withtechnological service offers and carrying out collaborative research projects will alsocontribute to facilitate Research & Development (R&D) projects.In 2010, ShareBiotech initiated a technological <strong>survey</strong> amongst their members(including academic laboratories and technological core facilities (1) , Biotechcompanies (2) and CROs (3) ) to identify the current technological needs. The <strong>survey</strong>revealed a strong demand in bioinformatics and more specifically the need for dataanalysis, management and storage.2 -‐ The technological needs in the Life Science market The sudden increase in “high content” technologies has created the need to structuredata management. Since the mid-90’s, correlated to the human genome sequencingachievement, “high content” technologies emerged, initially in genomics (sequencing,microarray, genotyping, SNP…) followed by proteomics (protein identification on 2D-LC-MSMS, protein microarray, biomarker identification…). By the year 2000, highcontent screening (screening of millions of molecules on a therapeutic target ofinterest) and metabolomics (metabolite identification using LS MS-MS) also requiredstrong data management. In fact, these ultra powerful “high content” technologiesgenerated massive amount of data useful in research to better understand diseasecauses and develop new therapies. The high content technologies have opened upnew perspectives to researchers and have allowed significant scientificbreakthrough.These “high content” processes are usually led in partnership between academiclaboratories and industries. Technologies are first developed by academics and theproof of concept is demonstrated by academics in pilot studies. When validated, thetechnologies are transferred to the industry for routine application.These technologies have initially been applied in human health and since theyprovided promising results, other Life Science sectors (animal health, agrofood,cosmetics, environment, biologic and medical chemistry) also adopted the tools.Considering the amount of data generated, data accumulation and transfer, the dataintegration in the R&D process has become a bottleneck, specifically in the Pharmaindustry since a reliable traceability of data is required to comply with regulation.(1)<strong>Technological</strong> core facilities are structures that provide a particular type of research material (such as dataacquisition, data analysis, consultation, and/or other service) and give access to technologies and services that aregenerally beyond the technical or financial capability of individual investigators. Often the use of these facilities isshared across departments and disciplines.(2)A Contract research organization (CRO) provides support to pharmaceutical and biotechnology industries asoutsourced services based on a contract agreement.(3)“Biotechs” stands for biotechnologies and have for main activities cellular and biomolecular techniques to developproducts or services for human health care, animal health care, agricultural productivity, food processing, renewableresources, industrial manufacturing and environmental management.4
Survey background 1 -‐ Background and objectives In 2010, ShareBiotech partners carried out a <strong>survey</strong> in France, Spain, Portugal andIreland amongst their members: 183 research groups and 143 companies working inthe field of Life Sciences were interviewed to understand R&D activities and identifytechnological needs and hurdles in their research activities. One of the conclusion ofthe study was a strong need for quality procedure, including data processing, datamanagement and transfer. Many research groups and companies expressed theneed to implement a clever data management system compatible with the currentdata management process in place in their institution/company.Considering the number of solutions available on the market (commercial software,open source, etc.), ShareBiotech decided to conduct a <strong>survey</strong> to better understandcurrent solution implemented and users expectations, in terms of quality, datatraceability, and compatibility.ShareBiotech appointed Novoptim to conduct a market <strong>survey</strong>, to advise and supportits members (academic laboratories and Biotech/CRO companies) in datamanagement.The main objective of the study is to understand the current status and practices indata management in the Life Science market (industry and academic) as well as toidentify the main solutions available.2 -‐ Methodology For the current project, Novoptim applied its proprietary and validated methodology.The geography of the study was focused on France.The target market was Life Science including Pharma, Biotech, Agrofood andCosmetics.The project was split in 2 phases (see Figure 1):- Phase 1: market research- Phase 2: field-based researchPhase 1 aimed at drawing the data management solution landscape, its trends andcurrent challenges, as well as the specifics of the Life Science market. Data wereextracted from journals and publications, interviews with Key Opinion Leaders, websearches, proprietary data, etc. The data collected was processed and thoroughlyanalyzed to draw the macro economical landscape.Phase 2 aimed at assessing the current needs and providing answers related to theimplementation of data management solutions, by probing the following marketactors:- LIMS/ELN suppliers- Potential users in academic organizations (academic laboratories andtechnological core facilities) and Biotech/CROs- Corporate groups (4)(4)Corporate groups are well-established companies with more than 250 employees and a turnover of at least 50M€(opposite to Small & Medium Enterprises (SMEs)).5
Page 1 and 2: Technological <str
Page 3: ) Implemented quality standards
Page 7 and 8: Computer data management system
Page 9 and 10: The implementation of data manageme
Page 11 and 12: While the vast majority of companie
Page 13 and 14: Figure 7 - LIMS and ELN solutions13
Page 15 and 16: Usage of ELN and LIMS also depends
Page 17 and 18: - Head of platform- Head of resourc
Page 19 and 20: - Need for innovation- Design of ne
Page 21 and 22: ) Implemented quality standards
Page 23 and 24: Nb. of respondents (N=30)3025201510
Page 25 and 26: The perceived benefits of implement
Page 27 and 28: Nb. of respondents (N=17)Surveyed r
Page 29 and 30: As indicated by the suppliers, the
Page 31 and 32: 2 -‐ Quality system The <str
Page 33 and 34: customized solutions since they are
Page 35 and 36: Appendix 1: Online surve
Page 37 and 38: □□□□Pas de besoin actuellem
Page 39 and 40: □□□□□Avantage concurrenti
Page 49 and 50: Appendix 3: Surveyed contact li
Page 51 and 52: Appendix 4: Peer recommendations
Page 53: B$: Billion DollarsCRO: Contract Re

Technological survey on LIMS and ELN in Life Sciences - Biogenouest

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?